Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $88 from $73 and keeps an Overweight rating on the shares following quarterly results. The firm says it is “certainly not sweating” the light revenue number, particularly given that the transition to the new specialty pharmacy supporting Korlym only took place in February. With Lifyorli now commercially available in platinum-resistant ovarian cancer, the upward revision to management’s 2026 total revenue guidance range was not surprising, Piper adds.